back
Get SIGNAL/NOISE in your inbox daily
A new model known as BoltzGen designs protein binders for any biological target from scratch. Developed at MIT, BoltzGen has shown promise for hard-to-treat targets in cancer and neurodegenerative diseases.
Recent Stories
Jan 14, 2026
GenAI In European B2B Marketing: Why Hesitation Is The Real Risk
European B2B marketers see the promise of generative AI, but strict regulations and technical hurdles often slow progress.
Jan 14, 2026ArenaRL: Scaling RL for Open-Ended Agents via Tournament-based…
Reinforcement learning has substantially improved the performance of LLM agents on tasks with verifiable outcomes, but it still struggles on open-ended agent tasks with vast solution spaces (e.g.,...
Jan 14, 2026Act surprised – Roblox AI-powered age verification doesn’t work
At this point, I kind of have to feel sorry for Roblox. The company came under increasing criticism for failing...